文献速递呼吸道感染呼吸危重症与机械通气

气泡持续气道正压通气治疗马拉维高危重症肺炎儿童:开放标签随机对照试验

Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial.
PubMed 文献 · Lancet Respir Med · 2019-09-24

在马拉维一家地区医院的儿科病房,非医师给予低流量鼻导管氧疗或鼻气泡CPAP(bCPAP)。在无每日医师监督的病房中,bCPAP未降低高危重症肺炎儿童的医院死亡率,且疑似不良事件更多。

要点

  • bCPAP组疑似治疗相关不良事件11例(3%),氧疗组1例(<1%)。
  • 无每日医师监督的儿科病房使用bCPAP可能带来既往未认识的风险。

核心结论

  • 在无每日医师监督的马拉维儿科病房,bCPAP未降低高危重症肺炎儿童的医院死亡率,且疑似不良事件更多。

研究设计与样本

  • 开放标签随机对照试验,在马拉维Salima地区医院儿科病房开展,纳入1-59月龄WHO定义重症肺炎且伴HIV感染/暴露、严重营养不良或血氧饱和度<90%的儿童。
  • 计划样本900例,入组644例后数据安全监查委员会因无效提前终止;氧疗组323例,bCPAP组321例,主要分析为意向性治疗。

主要发现

  • 氧疗组13例、bCPAP组17例缺乏住院结局,按失访处理。
  • bCPAP组疑似治疗相关不良事件11/321(3%),氧疗组1/323(<1%)。
  • 4例bCPAP组和1例氧疗组死亡被归类为可能误吸事件,1例bCPAP组死亡为可能气胸,6例bCPAP组非死亡事件包括鼻周皮肤破损。

临床怎么用

  • 在缺乏每日医师监督的非重症儿科病房,对高危重症肺炎儿童不应常规使用bCPAP替代氧疗。
  • bCPAP在特定人群和非重症监护环境中可能带来既往未认识的风险,需进一步评估后再推广。

局限性

  • 试验因无效提前终止,实际入组644例低于计划的900例。
  • 开放标签设计,非医师实施治疗,结果外推至有医师监督或重症监护环境需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pneumonia is the leading cause of death among children globally. Most pneumonia deaths in low-income and middle-income countries (LMICs) occur among children with HIV infection or exposure, severe malnutrition, or hypoxaemia despite antibiotics and oxygen. Non-invasive bubble continuous positive airway pressure (bCPAP) is considered a safe ventilation modality that might improve child pneumonia survival. bCPAP outcomes for high-risk African children with severe pneumonia are unknown. Since most child pneumonia hospitalisations in Africa occur in non-tertiary district hospitals without daily physician oversight, we aimed to examine whether bCPAP improves severe pneumonia mortality in such settings. METHODS: This open-label, randomised, controlled trial was done in the general paediatric ward of Salima District Hospital, Malawi. We enrolled children aged 1-59 months old with WHO-defined severe pneumonia and either HIV infection or exposure, severe malnutrition, or an oxygen saturation of less than 90%. Children were randomly assigned 1:1 to low-flow nasal cannula oxygen or nasal bCPAP. Non-physicians administered care; the primary outcome was hospital survival. Primary analyses were by intention-to-treat and interim and adverse events analyses per protocol. This trial is registered with ClinicalTrials.gov, number NCT02484183, and is closed. FINDINGS: We screened 1712 children for eligibility between June 23, 2015, and March 21, 2018. The data safety and monitoring board stopped the trial for futility after 644 of the intended 900 participants were enrolled. 323 children were randomly assigned to oxygen and 321 to bCPAP. 35 (11%) of 323 children who received oxygen died in hospital, as did 53 (17%) of 321 who received bCPAP (relative risk 1·52; 95% CI 1·02-2·27; p=0·036). 13 oxygen and 17 bCPAP patients lacked hospital outcomes and were considered lost to follow-up. Suspected adverse events related to treatment occurred in 11 (3%) of 321 children receiving bCPAP and 1 (<1%) of 323 children receiving oxygen. Four bCPAP and one oxygen group deaths were classified as probable aspiration episodes, one bCPAP death as probable pneumothorax, and six non-death bCPAP events included skin breakdown around the nares. INTERPRETATION: bCPAP treatment in a paediatric ward without daily physician supervision did not reduce hospital mortality among high-risk Malawian children with severe pneumonia, compared with oxygen. The use of bCPAP within certain patient populations and non-intensive care settings might carry risk that was not previously recognised. bCPAP in LMICs needs further evaluation before wider implementation for child pneumonia care. FUNDING: Bill & Melinda Gates Foundation, International AIDS Society, Health Empowering Humanity.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. McCollum ED, Mvalo T, Eckerle M, et al. Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial. Lancet Respir Med. 2019. PMID: 31562059. doi:10.1016/S2213-2600(19)30243-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。